#ASH15 Live Blog [Updating]

ASH-LogoMayo Clinic hematologists, hematopathologists, and a wide spectrum of allied health staff are in Orlando, Florida for the 57th American Society of Hematology Annual Meeting & Exhibition. Follow this blog for live updates from #ASH15 as we attend the conference, mingle with colleagues at booth #859, and have a little fun. Have a comment or photo to share? Send it to us on Twitter @MayoClinicLabs or Facebook.


Dec. 7 at 3:19 p.m. EST

#ASH15 Day Three Video Recap

ASH is an excellent annual opportunity for many of our colleagues to present their latest research discoveries and novel treatment approaches for hematologic disorders. This year, more than one hundred posters and oral presentations had at least one Mayo Clinic author. Of those Mayo presentations, our friends in the Department of Laboratory Medicine and Pathology had more than 30 posters and oral presentations focused on the role of the laboratory in the care of patients across the full spectrum of hematologic disorders. Congratulations to all of our colleagues for their accomplishments. We look forward to seeing what is in store next year in San Diego.


Dec. 7 at 11:47 a.m. EST

Oral and Poster Presentations: Monday, December 7

Our colleagues from the Mayo Clinic Department of Laboratory Medicine and Pathology will be presenting the following oral and poster presentations today:

2:45 P.M.
#3372     DELETIONAL HPFH AND DELTA BETA THALASSEMIA: CLOSING IN ON A POSSIBLE HB F SILENCER
 Oral Presentation. Session: 112. Thalassemia and Globin Gene Regulation: Understanding and Manipulating Globin Gene Regulation

5:00 P.M.
#131       STUDY OF THE SUBCLONAL MUTATIONS IN PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA
Oral Presentation. Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Clinical Implications of Genomic Studies of B-cell Lymphomas

5:45 P.M.
#834       PD-1 BLOCKADE WITH PEMBROLIZUMAB (MK-3475) IN RELAPSED/REFRACTORY CLL INCLUDING RICHTER TRANSFORMATION: AN EARLY EFFICACY REPORT FROM A PHASE 2 TRIAL (MC1485)
Oral Presentation. Session: 642. CLL: Therapy, excluding Transplantation: Relapsed/Refractory CLL Therapy Excluding Transplantation

#828       ASXL1 AND CBL MUTATIONS ARE INDEPENDENTLY PREDICTIVE OF INFERIOR SURVIVAL IN ADVANCED SYSTEMIC MASTOCYTOSIS
Oral Presentation. Session: 634. Myeloproliferative Syndromes: Clinical: Combination Therapy in MPN

6:00-8:00 P.M.
#3374     LARGE DELETIONS INVOLVING THE BETA GLOBIN GENE COMPLEX: GENOTYPE-PHENOTYPE CORRELATION OF 119 CASES
Session: 112. Thalassemia and Globin Gene Regulation: Poster III

#3476     PLATELET TRANSMISSION ELECTRON MICROSCOPY AND FLOW CYTOMETRY IN THE DIAGNOSIS OF CONGENITAL/HEREDITARY QUALITATIVE OR QUANTITATIVE PLATELET DISORDERS
Session: 311. Disorders of Platelet Number or Function: Poster III

#3922     COMPREHENSIVE ANALYSES OF GENETIC FEATURES IDENTIFY COORDINATE SIGNATURES IN DIFFUSE LARGE B-CELL LYMPHOMA
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster III

#3947     TISSUE IS THE ISSUE:  ACCURACY OF PET IMAGING TO DETECT BONE MARROW CLEARANCE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III

#4062     MOMELOTINIB THERAPY FOR MYELOFIBROSIS: IMPACT ON LONG-TERM SURVIVAL AND GENOTYPE CORRELATIONS
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

#4068     MOLECULAR CORRELATES OF ANEMIA IN PRIMARY MYELOFIBROSIS
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

#4067     VASCULAR EVENTS AND RISK FACTORS FOR THROMBOSIS IN REFRACTORY ANEMIA WITH RING SIDEROBLASTS AND THROMBOCYTOSIS (RARS-T)
Session: 634. Myeloproliferative Syndromes: Clinical: Poster III

#4176     OCCURRENCE AND PROGNOSTIC SIGNIFICANCE OF CYTOGENETIC EVOLUTION IN PATIENTS WITH MULTIPLE MYELOMA
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III


Dec. 7 at 10:39 a.m. EST

Intensive Therapy Strategies in Older Patients With AML Remain Standard of Care

According to results of a phase 3 trial presented at the 57th American Society of Hematology (ASH) Annual Meeting, single-agent clofarabine is inferior to standard therapy with daunorubicin and cytarabine in older patients with newly diagnosed acute myeloid leukemia (AML) who are fit for intensive therapy.

Foran
James Foran, M.D.

The daunorubicin and cytarabine 7&3 induction “remains the standard of care for older adults being treated with ‘curative intent,'” said James Foran, M.D., of the Mayo Clinic Cancer Center in Jacksonville, FL.

These results “suggest the importance of maintaining intensive therapy strategies in older AML patients 60 years or older whenever possible and appropriate,” he added.

Based on the primary weighted analysis for overall survival, on February 23, 2015, the trial's data safety monitoring committee recommended suspension of new accrual and all active patients on clofarabine were transitioned to the daunorubicin and cytarabine arm, he reported.

Read the full article for more information on the study.


Dec. 6 at 8:45 a.m. EST

#ASH15 Day Two Video Recap: Social Media for Hematologists

By Day Two, the hashtag "#ASH15" was trending on Twitter. Perfect timing for a special session on "Social Media for the Hematologist." The session was chaired by @MayoClinic hematologist Joseph Mikhael, M.D., a member of the ASH Communications Committee. Today's panel discussion brought together some of the leading hematology voices on Twitter who shared their experiences and advice for optimizing the platform to effectively communicate with colleagues, stay up to date on the latest news and research, and engage patient advocates and patients. We caught up with Dr. Mikhael after his session and recorded the brief interview embedded above.

Additionally, colleagues from throughout Mayo Clinic presented a number of oral presentations and posters on Sunday. Of the large number of Mayo Clinic posters, 14 were specifically related to advances in laboratory testing approaches across the full spectrum of hematologic disorders.


Dec. 6 at 3:15 p.m. EST

Oral and Poster Presentations: Sunday, December 6

Our colleagues from the Mayo Clinic Department of Laboratory Medicine and Pathology will be presenting the following oral and poster presentations today:

4:45 P.M.
#350      
A 27-GENE NGS PANEL IN PRIMARY MYELOFIBROSIS IDENTIFIES ASXL1, CBL, RUNX1 AND SRSF2 MUTATIONS AS BEING UNFAVORABLE AND ABSENCE OF ANY NON-DRIVER MUTATION AS BEING FAVORABLE TO SURVIVAL
Oral Presentation. Session: 634. Myeloproliferative Syndromes: Clinical: Molecular Genetics and Prognosis of MPN

5:45 P.M.
#354      
TARGETED NEXT-GENERATION SEQUENCING IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
 Oral Presentation. Session: 634. Myeloproliferative Syndromes: Clinical: Molecular Genetics and Prognosis of MPN

6:00-8:00 P.M.
#2140    
SPECTRUM OF MUTATIONS ASSOCIATED WITH HEREDITARY ERYTHROCYTOSIS
Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II

#2802     CD123 IMMUNOSTAINING IN SYSTEMIC MASTOCYTOSIS: DIFFERENTIAL EXPRESSION IN DISEASE SUBGROUPS AND POTENTIAL PROGNOSTIC VALUE
Session: 634. Myeloproliferative Syndromes: Clinical: Poster II

#2306     A COMPARISON OF VON WILLEBRAND FACTOR INDEXES IN HEARTMATE II COMPARED TO HEARTWARE LEFT VENTRICULAR ASSIST DEVICES
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II

#2681     MUTATIONS TARGETING THE ERBB PATHWAY AND MSC IN PERIPHERAL T-CELL LYMPHOMA
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II

#2673     UCH-L1 COOPERATES WITH BCL6 AND IDENTIFIES PATIENTS WITH AGGRESSIVE GERMINAL CENTER DIFFUSE
LARGE B-CELL LYMPHOMA
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II

#2801     DRIVER MUTATIONS AND PROGNOSIS IN 1118 PATIENTS WITH PRIMARY MYELOFIBROSIS
Session: 634. Myeloproliferative Syndromes: Clinical: Poster II

#2935     IBRUTINIB THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ANALYSIS OF A LARGE COHORT OF PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE
Session: 642. CLL: Therapy, excluding Transplantation: Poster II

#2882     ASXL1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES WITH 1% OR MORE RING SIDEROBLASTS: PREVALENCE, CLINICAL CORRELATES AND PROGNOSTIC RELEVANCE
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II

#2864     PROGNOSTIC INTERACTION BETWEEN ASXL1 AND TET2 MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II

#2805     SURVIVAL TRENDS IN ESSENTIAL THROMBOCYTHEMIA IN THE FACE OF CHANGING TREATMENT PRACTICES
Session: 634. Myeloproliferative Syndromes: Clinical: Poster II

#2919     CENTRAL NERVOUS SYSTEM INVOLVEMENT BY CHRONIC LYMPHOCYTIC LEUKEMIA
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster II

#2875     SURVIVAL TRENDS IN PRIMARY MYELODYSPLASTIC SYNDROMES: A COMPARATIVE ANALYSIS OF 1000 PATIENTS BY YEAR OF DIAGNOSIS AND TREATMENT
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II


Dec. 6 at 8:45 a.m. EST

#ASH15 Day One Video Recap


On the first day of the American Society of Hematology Annual Meeting and Exhibition, we launched our new interactive hematology case studies called, "Power Up Your Knowledge." This interactive station, located at booth #859, allows attendees to review ten case studies on a full spectrum of hematologic disorders. Also on tap today were 4 posters from our colleagues in Mayo Clinic's Department of Laboratory Medicine and Pathology along with countless others from around Mayo Clinic.


Dec. 6 at 8:15 a.m. EST

Pre-Conference Symposium Video Recap


On Friday morning, Mayo Medical Laboratories hosted a four-hour scientific symposium, which brought together more than 360 hematology and hematopathology experts from around the world. The symposium was titled, "Algorithmic Approaches to Coagulation Testing: What a Hematologist Should Know." Featured speakers were doctors William Nichols, Rong He, Dong Chen, Rajiv Pruthi, C. Christopher Hook, and Deepti Warad. For those unable to attend or those wishing to watch it again, slides and video will be posted on MayoMedicalLaboratories.com in the coming weeks. Thank you to everyone who attended this year's symposium.


Dec. 5 at 7:42 p.m. EST

#ASH15 Day One is in the Books

We're guessing this might be the coolest sign in conference history. A living hematology sign was an amazing sight to see, especially at night. Check back tomorrow for two video updates and a couple other surprises.

ash2015-sat-night

 


Dec. 5 at 3:15 p.m. EST

Power Up Your Knowledge 

Attendees have been visiting our Power Up Your Knowledge station to review ten case studies that span the full spectrum of hematologic disorders. For those unable to attend ASH this year, we also have an online version available.

power-up-1

power-up-2


Dec. 5 at 2:09 p.m. EST

Oral and Poster presentations: Saturday, December 5

This evening, our colleagues from the Mayo Clinic Department of Laboratory Medicine and Pathology will be presenting the following oral and poster presentations between 5:30-7:30 p.m. in the Exhibit Hall.

#1061     VALUE OF PLATELET ESOTERIC TESTING IN LABORATORY DIAGNOSIS OF PLATELET DISORDERS: A SINGLE CENTER EXPERIENCE
Session: 311. Disorders of Platelet Number or Function: Poster I

#1050     NOVEL GENETIC VARIANTS IN COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHY
Session: 311. Disorders of Platelet Number or Function: Poster I

#1501     EVENT-FREE SURVIVAL AT 12 MONTHS AND SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH PERIPHERAL
T-CELL LYMPHOMA
Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I

#1599     DRIVER MUTATIONS AND PROGNOSIS IN 502 PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
Session: 634. Myeloproliferative Syndromes: Clinical: Poster I


Dec. 5 at 11:00 a.m. EST

The Exhibit Hall is Open!

Be sure to visit us at booth #859 to discuss testing across the whole spectrum of hematologic disorders.

ash2015-sat-booth

ash2015-sat-staff

 


Dec. 5 at 7:21 a.m. EST

Good Morning!

It’s a beautiful morning in Orlando and we’re ready to head over to the convention center. Considering there’s snow on the ground in Minnesota, we're liking this weather!

ash2015-sat-morning2

ash2015-sat-morning


Dec. 4 at 11:58 a.m. EST

Thank You to Our Pre-Conference Symposium Faculty

A special thank you to our pre-conference symposium faculty for their presentations. Pictured from left to right: Dong Chen, M.D., Ph.D., Rong He, M.D., C. Christopher Hook, M.D., William L. Nichols, M.D., Deepti M. Warad, M.B.B.S., and Rajiv K. Pruthi, M.B.B.S.

IMG_1035
Pictured from left to right: Dong Chen, M.D., Ph.D., Rong He, M.D., C. Christopher Hook, M.D., William L. Nichols, M.D., Deepti M. Warad, M.B.B.S., and Rajiv K. Pruthi, M.B.B.S.

Dec. 4 at 10:07 a.m. EST

Mayo Medical Laboratories Pre-Conference Symposium

Our Satellite Symposium preceding the 57th ASH Annual Meeting kicked off this morning. With a variety of presentations and discussion, the symposium is designed to inform participants about cost-effective, diagnostically efficient test ordering strategies for evaluation of prolonged screening clotting time tests (PT, APTT), screening and esoteric testing for the patient with bleeding symptoms, lupus anticoagulant testing, laboratory evaluation of thrombophilia and thrombotic microangiopathy, and pediatric coagulation testing. Using test ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and the literature, we will illustrate how costly and unnecessary biochemical, phenotypic and genetic testing can be avoided for the participants’ practices while enhancing highest quality medical care.

Participants have the opportunity to hear from our renowned faculty and enjoy the following presentations:

  • Prolonged APTT and PT
  • Evaluation of the Bleeding Patient: Screening Tests
  • Evaluation of the Bleeding Patient: Esoteric Tests
  • Lupus Anticoagulant and Antiphospholipid Antibodies: Testing Guidelines
  • Algorithmic Thrombophilia Testing
  • Rational Approach to Evaluation of Thrombotic Microangiopathy
  • Challenges in Pediatric Coagulation Testing

 

kschrib

Kelley Schreiber

Kelley Schreiber is a Marketing Channel Manager at Mayo Medical Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her new kitten, and exploring new foods.

Responses

Do we have access to the Pre-conference slides?

Hi Abebe, please email Sharon Preuss (Preuss.Sharon@mayo.edu) to receive the information to access the pre-conference slides. Thank you!

Comments are closed.